Traders should monitor for follow-up clinical updates, potential partnership announcements, or changes in analyst coverage. The strong safety and efficacy data in a high-unmet-need population could catalyze investor interest in this micro-cap biotech, though the small market cap ($4M) suggests high risk and potential for volatility.
Price Chart
Executive Summary
Aptevo Therapeutics announced positive interim clinical data for its drug candidate mipletamig in combination with venetoclax and azacitidine for newly diagnosed AML patients. The data showed an 86% clinical benefit rate, 79% complete remission or CRi rate, and no cases of cytokine release syndrome (CRS) in 28 evaluable patients. These results highlight a promising efficacy and safety profile for a high-risk patient population.
Key Facts
- Interim data from 28 evaluable AML patients (24 from RAINIER trial, 4 from dose expansion) showed 86% clinical benefit rate (CR/CRi/PR)
- 79% achieved complete remission (CR) or CR with incomplete recovery (CRi), 61% achieved CR
- 100% of patients remained free of cytokine release syndrome (CRS), a significant safety advantage
- 55% of patients achieving CR/CRi reached measurable residual disease (MRD)-negative status, associated with durable responses
- 35% of responding patients had the high-risk TP53 mutation, typically linked to poor prognosis and treatment failure
- Four patients proceeded to allogeneic stem cell transplant, considered the best outcome in AML
Financial Impact
No direct financial impact quantified in filing, but strong clinical data significantly increases the potential value of mipletamig and improves Aptevo's prospects for partnerships, funding, or regulatory advancement
Risk Factors
- Interim data from a small sample size (n=28); results may not be replicated in larger trials
- Data is from a combination therapy, making it difficult to isolate mipletamig's contribution
- Company has a small market cap ($4M), indicating high financial risk and potential liquidity concerns
- Forward-looking statements include risks related to clinical trial progression, regulatory approval, and financing needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-100539 |
| Document: apvo-ex99_1.htm | 0001193125-26-100539 |
| Document: 0001193125-26-100539-index-headers.html | 0001193125-26-100539 |
| Document: 0001193125-26-100539-index.html | 0001193125-26-100539 |
| Document: 0001193125-26-100539.txt | 0001193125-26-100539 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $1.73 | awaiting T+5 | — | $1.50 (−13.38%) |
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+5 | — | $1.50 (−6.83%) |
Oct 14, 2026 13d ago | 8-K | $1.73 $1.60 | ▼ −7.51% | ▼ −7.97% | $1.50 (−13.29%) |
Sep 24, 2026 4w ago | 8-K | $1.83 $1.76 | ▼ −3.83% | ▼ −3.41% | $1.50 (−18.03%) |
Sep 3, 2026 7w ago | 424B4 / 8-K | $1.71 $1.82 | ▲ +6.43% | ▲ +7.58% | $1.50 (−12.28%) |
Sep 3, 2026 7w ago | EFFECT | $1.71 $1.82 | ▼ −6.43% | ▼ −7.58% | $1.50 (+12.28%) |
Aug 14, 2026 10w ago | 8-K | $2.94 $2.68 | ▼ −8.84% | ▼ −7.48% | $1.50 (−48.98%) |
Jul 27, 2026 13w ago | 8-K | $4.21 $3.95 | ▼ −6.18% | ▼ −8.44% | $1.50 (−64.37%) |
Jun 30, 2026 16w ago | 8-K | $4.45 $4.51 | ▲ +1.35% | ▲ +1.09% | $1.50 (−66.29%) |
May 6, 2026 24w ago | 8-K | $4.86 $4.76 | ▼ −2.06% | ▼ −3.56% | $1.50 (−69.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers